glp 1 and glp 2 drugs GLP-1 from the Gray Market A Big Week for GLP-1

Individual ingredient amounts in the proprietary blend aren't disclosed - that's a standard proprietary-blend format, not unique to this product

The pattern is that both are GI-forward drugs, but retatrutides glucagon activity adds a cardiovascular consideration (heart rate) that cagrilintides amylin mechanism does not, and the same potency that produces retatrutides larger weight loss is associated, in indirect analyses, with a heavier adverse-event load

As with any health issue, professional guidance ensures the best outcomes

Benoist 2014, PMID 25187433, retraction notice PMID 40312093), and a third carries a 2021 Expression of Concern (McCoy 2013, PMID 23055539)

Its mechanisms are broad and systemic, meaning it can benefit tissues throughout the body

This means it doesn't necessarily kill all bacteria, but it prevents them from growing and multiplying within the vial